A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumour (GIST) Patients.

Trial Profile

A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumour (GIST) Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Imatinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Aug 2010 Merck and Co added as trial sponsor and Schering/Merck as lead trial centre as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top